NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/18/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,932.32 mln
Float85.84 mln
Earnings Date08/19/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
12.94
Highly suspicious
1-Year Forecast
40.10
Transformational upside
Relative Strength
94
/ 100
Top performer
Debt / Equity
0.06
Debt-free
ROE
-62.26
Deeply negative
Business Description
Alumis Inc. is a drug development company based in South San Francisco, California, working to bring new treatments to patients with autoimmune and inflammatory conditions. Its leading drug candidate targets a protein called TYK2, which plays a key role in driving diseases such as plaque psoriasis and lupus, while a second compound in early-stage testing aims to address inflammation in the brain and nervous system. The company is also developing treatments for thyroid eye disease and broader immune system disorders. Founded in 2021 under the name Esker Therapeutics, Alumis is working to build a focused portfolio of medicines in areas where patients still have limited options.
